About
Gano has worked at Neurocrine for more than two decades. He held several positions from 2001 to 2011, spanning marketing analytics to business development, then served as chief business development officer from 2011 and as chief business development and strategy officer from 2020 until becoming CEO. He received B.S. degrees in chemistry from the University of Oregon and in biochemistry from the University of Washington, and an M.B.A. and a Ph.D. in organic chemistry from the University of California, Los Angeles. Other pharmaceutical leaders with pages on Whoo include Daniel O'Day of Gilead Sciences and David Ricks of Eli Lilly.
Whoo compiled this page from public sources: Neurocrine third-quarter 2026 results release (SEC filing), Neurocrine 2026 proxy statement (SEC filing), Neurocrine 2025 annual report (Form 10-K). It is not affiliated with or endorsed by Kyle Gano. Are you Kyle Gano? Claim this page, or write to [email protected] to correct or remove it. Last updated: 2026-11-18.
Want a page like this? Create yours from your résumé.
Experience
President and Chief Executive Officer — Neurocrine Biosciences
October 2024 – Present | San Diego, California
- Board member since October 2024
- Held several positions spanning marketing analytics to business development
Chief Business Development and Strategy Officer — Neurocrine Biosciences
2020 – 2024
Chief Business Development Officer — Neurocrine Biosciences
2011 – 2020
Neurocrine Biosciences
2001 – 2011